Full Length Research Paper
References
|
Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, Kaufman P, Conwit RA, Schoenfeld D, Shefner J, Cudkowicz M (2010). Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 9(5):481-488. |
|
|
Ahn SW, Jeon GS, Kim MJ, Shon JH, Kim JE, Shin JY, Kim SM, Kim SH, Ye, IH, Lee KW Hong YH (2014). Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis. J. Neurol. Sci. 340(1-2):112-116. |
|
|
Atassi N, Ratai EM, Greenblatt DJ, Pulley D, Zhao Y, Bombardier J, Wallace S, Eckenrode J, Cudkowicz M, Dibernardo A (2010). A phase I pharmacokinetic dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 11(6):508-513. |
|
|
Bame M, Pentiak PA, Needleman R, Brusilow WS (2012). Effect of sex on lifespan, disease progression, and the response to methionine sulfoximine in the SOD1 G93A mouse model for ALS. Gend Med. 9(6):524-535. |
|
|
Beghi E, Chiò A, Couratier P, Esteban J, Hardiman O, Logroscino G, Millul A, Mitchell D, Preux PM, Pupillo E, Stevic Z (2011). The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler. 12(1):1-10. |
|
|
Beghi E, Pupillo E, Bonito V, Buzzi P, Caponnetto C, Chiò A, Corbo M, Giannini F, Inghilleri M, Bella VL, Logroscino G (2013). Randomized double-blind placebo-controlled trial of acetyl-l-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener.14(5-6):397-405. |
|
|
Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB (2013). Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One 8(4):e61177. |
|
|
Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW (2006). Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312(5778):1389-1392. |
|
|
Boll MC, Bayliss L, Vargas-Ca-as S, Burgos J, Montes S, Pe-aloza-Solano G, Rios C, Alcaraz-Zubeldia M (2014). Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis. J. Neurol. Sci. 340(1-2):103-108. |
|
|
Calderó J, Brunet N, Tarabal O, Piedrafita L, Hereu M, Ayala V, Esquerda JE (2010). Lithium prevents excitotoxic cell death of motoneurons in organotypic slice cultures of spinal cord. Neuroscience 165(4):1353-1369. |
|
|
Cappello V, Vezzoli E, Righi M, Fosati M, Mariotti R, Crespi A, Patruno M, Bentivoglio M, Pietrini G, Francolini M (2012). Analysis of neuromuscular junctions and effects of anabolic steroid administration in the SOD1G93A mouse model f ALS. Mol. Cell Neurosci. 51(1):12-21. |
|
|
Chiò A, Borghero G, Calvo A, Capasso M, Caponnetto C, Corbo M, Giannini F, Logroscino G, Mandrioli J, Marcello N, Mazzini L (2010). Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology 75(7):619-625. |
|
|
Chiò A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, White LA (2013). Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41(2):118-130. |
|
|
Chiò A, Mora G, La Bella V, Caponnetto C, Mancardi G, Sabatelli M, Siciliano G, Silani V, Corbo M, Moglia C Calvo A (2011). Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study. Muscle Nerve 43(2):189-195. |
|
|
Costa J, Swash M, de Carvalho M (2012). Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. Arch Neurol. 69(11):1410-1416. |
|
|
Couglan KS, Mitchem MR, Hogg MC, Prehn JH (2015). "Preconditioning" with latrepirdine, an adenosine 5'-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice. Neurobiol. Aging 36(2):1140-1150. |
|
|
Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, Moore DH, Schoenfeld D, Mather JL, Archibald D, Sullivan M (2011). The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nature Med. 17(12):1652-1656. |
|
|
Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, Hayden D, Shui A, Brooks B, Conwit R, Felsenstein D (2014). Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 13(11):1083-1091. |
|
|
Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL (2013). Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 12(11):1059-1067. |
|
|
Dodge JC, Treleaven CM, Fidler JA, Hester M, Haidet A, Handy C, Rao M, Eagle A, Matthews JC, Taksir TV Cheng SH (2010). AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol. Ther. 18(12):2075-2084. |
|
|
Dorst J, Cypionka J, Ludolph AC (2013) High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional study. Amyotroph. Lateral Scler. Frontotemporal Degener. 14(7-8):533-536. |
|
|
Duning T, Schiffbauer H, Warnecke T, Mohammadi S, Floel A, Kolpatzik K, Kugel H, Schneider A, Knecht S, Deppe M, Schäbitz WR (2011). G-CSF prevents the progression of structural disintegration of white matter tracts in amyotrophic lateral sclerosis: a pilot trial. PLoS One 6(3):e17770. |
|
|
Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, Fischer W, Steiner F, Lindauer E, Otto M, Dreyhaupt J (2012). A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS ONE 7(6):e37885. |
|
|
Feng XH, Yuan W, Peng Y, Liu MS, Cui LY (2012). Therapeutic effects of dl-3-n-butylphthalide in a transgenic mouse model of amyotrophic lateral sclerosis. Chin Med. J. (Engl). 125(10):1760-1766. |
|
|
Ferrucci M, Spalloni A, Bartalucci A (2010). A systematic study of brainstem motor nuclei in a mouse model of ALS, the effects of lithium. Neurobiol Dis. 37(2):370-383. |
|
|
Fidler J, Treleaven CM, Frakes A (2011). Disease progression in a mouse model of amyotrophic lateral sclerosis: the influence of chronic stress and corticosterone. FASEB J. 25(12):4369-4377. |
|
|
Fondell E, O'Reilly ÉJ, Fitzgerald KC, Falcone GJ, McCullough ML, Thun MJ, Park Y, Kolonel LN, Ascherio A (2012). Non-steroidal anti-inflammatory drugs and amyotrophic lateral sclerosis: results from five prospective cohort studies. Amyotroph. Lateral Scler. 13(6):573-579 |
|
|
Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, Lazzeri G, Spalloni A, Bellio N, Lenzi P, Modugno N (2008). Lithium delays progression of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U S A. 105(6):2052-2057. |
|
|
Gerber YN, Privat A, Perrin FE (2013). Gacyclidine improves the survival and reduces motor deficits in a mouse model of amyotrophic lateral sclerosis. Front Cell Neurosci. 7:280. |
|
|
Ghoddoussi F, Galloway MP, Jambekar A, Bame M, Needleman R, Brusilow WS (2010). Methionine sulfoximine, an inhibitor of glutamine synthetase, lowers brain glutamine and glutamate in a mouse model of ALS. J. Neurol. Sci. 290(1-2):41-47. |
|
|
Gianforcaro A, Hamadeh M (2012). Dietary Vitamin D3 Supplementation at 10X the adequate intaque improves functional capacity in the G93A transgenic mouse model of ALS, a pilot study. Neurosci ther.18: 547-557. |
|
|
Gianforcaro A, Solomon J, Hamadeh M (2013). Vitamin D3 at 5-X Al Attenuates the decline in paw grip endurance, but not disease outcomes, in te G93A Mouse Modelo of ALS, and is Toxic in Females. PloS ONE 8(2):e30243. |
|
|
Gordon PH (2013). Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials. Aging Dis. 4(5):295-310. |
|
|
Gordon PH, Meininger V (2011). How can we improve clinical trials in amyotrophic lateral sclerosis? Nat. Rev. Neurol. 7:650-654. |
|
|
Goursaud S, Schäfer S, Dumont AO, Vergouts M, Gallo A, Desmet N, Deumens R, Hermans E (2015). The anti-inflammatory peptide stearyl-norleucine-VIP delays disease onset and extends survival in a rat model of inherited amyotrophic lateral sclerosis. Exp. Neurol. 263:91-101. |
|
|
Grad LI, Fernando SM, Cashman NR (2015). From molecule to molecule and cell to cell: prion-like mechanisms in amyotrophic lateral sclerosis. Neurobiol Dis. 77:257-265. |
|
|
Grassinger J, Khomenko A, Hart C, Baldaranov D, Johannesen SW, Mueller G, Schelker R, Schulte-Mattler W, Andreesen R, Bogdahn U (2014). Safety and feasibility of long term administration of recombinant human granulocyte-colony stimulating factor in patients with amyotrophic lateral sclerosis. Cytokine 67(1):21-28. |
|
|
Gu R, Hou X, Pang R, Li L, Chen F, Geng J, Xu Y, Zhang C (2010). Human adipose-derived stem cells enhance the glutamate uptake function of GLT1 in SOD1G93A-bearing astrocytes. Biochem. Biophys. Res Com. 393(3):481-486. |
|
|
Guo Y, Zhang K, Wang Q, Li Z, Yin Y, Xu Q, Duan W, Li C (2011). Neuroprotective effects of diallyl trisulfide in SOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis. Brain Res. 1374:110-115. |
|
|
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ (2008). GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924-926. |
|
|
Hayes-Punzo A, Mulcrone P, Meyer M, McHugh J, Svendsen CN, Suzuki M (2012). Gonadectomy and dehydroepiandrosterone (DHEA) do not modulate disease progression in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 13(3):311-314. |
|
|
Henriques A, Pitzer C, Dittgen T, Klugmann M, Dupuis L, Schneider A (2011). CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit. Mol. Ther. 19(2):284-292. |
|
|
Jablonka S, Holtmann B, Sendtner M (2011). Therapeutic effects of PEGylated insulin-like growth factor I in the pmn mouse model of motoneuron disease. Exp. neurol. 232:261-269. |
|
|
Jiang HQ, Ren M, Jiang HZ, Wang J, Zhang J, Yin X, Wang SY, Qi Y, Wang XD, Feng HL (2014). Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neuroscience 277:132-138. |
|
|
Kaneb HM, Sharp PS, Rahmani-Kondori N, Wells DJ (2011) Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1 (G93A) mouse model of ALS and is harmful in female mice. PLoS ONE 6(9):e24189. |
|
|
Katsumata R, Ishigaki S, Katsuno M, Kawai K, Sone J, Huang Z, Adachi H, Tanaka F, Urano F, Sobue G (2012). c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis. PLoS ONE 7(9):e46185. |
|
|
Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, Krivickas LS, Katz J, Rollins Y, Barohn RJ, Jackson CE, Tiryaki E (2009). Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 66(2):235-244. |
|
|
Keller AF, Gravel M, Kriz J.(2011) Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp Neurol. 228(1):69-79. |
|
|
Kung J, Chiappelli F, Cajulis OO, Avezova R, Kossan G, Chew L, Maida CA (2010). From systematic reviews to clinical recommendations for evidence-based health care: validation of revised assessment of multiple systematic reviews (R-AMSTAR) for grading of clinical relevance. Open Dent. J. 4:84-91. |
|
|
Le Pichon CE, Dominguez SL, Solanoy H, Ngu H, Lewin-Koh N, Chen M, Eastham-Anderson J, Watts R, Scearce-Levie K (2013). EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS. PLoS ONE 8(4):e62342. |
|
|
Lenglet T, Lacomblez L, Abitbol JL, Ludolph A, Mora JS, Robberecht W, Shaw PJ, Pruss RM, Cuvier V, Meininger V (2014). A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur. J. Neurol. 21(3):529-536. |
|
|
Li J, Sung M, Rutkove SB (2013) Electrophysiologic biomarkers for assessing disease progression and the effect of riluzole in SOD1 G93A ALS mice. PLoS ONE 8(6):e65976. |
|
|
Linares E, Seixas LV, dos Prazeres JN (2013). Tempol moderately extends survival in a hSOD1 (G93A) ALS rat model by inhibiting neuronal cell loss, oxidative damage and levels of non-native hSOD1(G93A) forms. PLoS ONE 8(2):e55868. |
|
|
Logroscino G, Traynor BJ, Hardiman O, Chio A, Mitchell D, Swingler RJ, Millul A, Benn E, Beghi E (2010). Incidence of amyotrophic lateral sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry 81(4):385-390. |
|
|
Lougheed R, Turnbull J (2011). Lack of effect of methylene blue in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. PLoS ONE. 6(10):e23141. |
|
|
Lucchetti J, Marino M, Papa S, Tortarolo M, Guiso G, Pozzi S, Bonetto V, Caccia S, Beghi E, Bendotti C, Gobbi M (2013). A mouse model of familial ALS has increased CNS levels of endogenous ubiquinol9/10 and does not benefit from exogenous administration of ubiquinol10. PLoS ONE 8(7):e69540. |
|
|
Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler JP, Mead R, Niessen HG, Petri S, Pradat PF, Robberecht W (2010) Guidelines for preclinical animal research in ALS/MND: A consensus meeting.Amyotroph Lateral Scler.11(1-2):38-45. |
|
|
Mancuso R, del Valle J, Modol L, Martinez A, Granado-Serrano AB, Ramirez-Nú-ez O, et al. (2014) Resveratrol improves motoneuron function and extends survival in DOD1(G93A) ALS mice. Neurotherapeutics 11(2):419-432. |
|
|
Mancuso R, Navarro X. (2015) Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic. Prog. Neurobiol. 133:1-26 |
|
|
Mancuso R, Oliván S, Rando A, Casas C, Osta R, Navarro X (2012). Sigma-1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics. 9(4):814-826. |
|
|
Marin B, Gil J, Preux PM, Funalot B, Couratier P (2009) Incidence of amyotrophic lateral sclerosis in the Limousin region of France, 1997-2007. Amyotroph. Lateral Scler.10:216-220. |
|
|
Markert CD, Kim E, Gifondorwa DJ, Childers MK, Milligan CE (2010). A single-dose resveratrol treatment in a mouse model of amyotrophic lateral sclerosis. J. Med. Food13(5):1081-1085. |
|
|
Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C (2009). Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73(15):1218-1226. |
|
|
Miller RG, Mitchell JD, Moore DH (1997). Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 3:CD001447. |
|
|
Min JH, Hong YH, Sung JJ, Kim SM, Lee JB, Lee KW (2012). Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial. J. Korean Med. Sci. 27(2):200-206. |
|
|
Nefussy B, Artamonov I, Deutsch V, Naparstek E, Nagler A, Drory VE (2010). Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study. Amyotroph Lateral Scler 11(1-2): 187-193. |
|
|
Orrell RW (2010). Motor neuron disease: systematic reviews of treatment for ALS and SMA. Br. Med. Bull. 93:145-159 |
|
|
Paganoni S, Macklin EA, Lee A (2014). Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener. 15(5-6):453-456. |
|
|
Pascuzzi RM, Shefner J, Chappell AS, Bjerke JS, Tamura R, Chaudhry V, Clawson L, Haas L, Rothstein JD (2010). A phase II trial of talampanel in subjects with Amyotrophic Lateral Sclerosis. Amyotroph Later Scler. 11(13):266-271. |
|
|
Pasquali L, Longone P, Isidoro C, Ruggieri S, Paparelli A, Fornai F (2009). Autophagy, lithium, and amyotrophic lateral sclerosis. Muscle Nerve 40(2):173-194. |
|
|
Pastula DM, Moore DH, Bedlack RS (2012). Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst. Rev. 12:CD005225. |
|
|
Perrin S (2012). Preclinical research: make mouse studies work. Nature. 507(7493):423-425. |
|
|
Pizzasegola C, Caron I, Daleno C (2009). Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. Amyotroph Lateral Scler. 10(4):221-228. |
|
|
Ravits J, Appel S, Baloh RH, Barohn R, Brooks BR, Elman L, Floeter MK, Henderson C, Lomen-Hoerth C, Macklis JD, McCluskey L (2013). Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph. Lateral Scler. Frontotemporal Degener. 14(sup1):5-18. |
|
|
Roberts BR, Lim NK, McAllum EJ, Donnelly PS, Hare DJ, Doble PA, Turner BJ, Price KA, Lim SC, Paterson BM, Hickey JL (2014) Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 34(23):8021-8031. |
|
|
Rudnicki SA, Berry JD, Ingersoll E, Archibald D, Cudkowicz ME, Kerr DA, Dong Y (2013). Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral scler. Frontotemporal Degener. 14(1):44-51. |
|
|
Saccà F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Perrotta G, Carotenuto B, Marsili A, Palma V, De Michele G, Brunetti A (2012). A randomized controlled trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging and hormonal results. J Neurol. 259(1):132-138. |
|
|
Saenger S, Holtmann B, Nilges MR, Schroeder S, Hoeflich A, Kletzl H, Spooren W, Ostrowitzki S, Hanania T, Sendtner M, Metzger F (2012). Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity. Amyotroph Lateral Scler. 13(5):418-429. |
|
|
Schmitt F, Hussain G, Dupuis L, Loeffler JP, Henriques A (2014) A plural hole for lipids in motor neuron diseases: energy, signaling and structure. Frontiers Cell Neurosci. 8:1-10. |
|
|
Schuster J, Fu R, Heckman CJ (2010). Fluoxetine treatment has modest effects on disease progression in the mSOD1G93A mouse model of ALS. Amyotroph Lateral Scler. 11(1) 72-73. |
|
|
Schuster JE, Fu R, Siddique T, Heckman CJ (2012). Effect of prolonged riluzole on cultured motoneurons in a mouse model of ALS. J. Neurophysiol. 107(1):484-492. |
|
|
Seo JS, Baek IS, Leem YH, Kim TK, Cho Y, Lee SM, Park YH, Han PL (2011). SK-PC-B70M alleviates neurologic symptoms in G93A-SOD1 amyotrophic lateral sclerosis mice. Brain Res.1368:299-307. |
|
|
Song L, Chen L, Zhang X, Li J, Le W (2014). Resveratrol ameliorates motor neuron degeneration and improves survival in SOD1(G93A) mouse model of amyotrophc lateral sclerosis. Biomed. Res. Int. 2014:483501. |
|
|
Soon CPW, Donelly OS, Turner BJ (2011). Diacetylbis (N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J. Biol. Chem. 286(51):44035-44044. |
|
|
Staats KA, Van Rillaer M, Scheveneels W, Verbesselt R, Van Damme P, Robberecht W, Van Den Bosch L (2012). Dantrolene is neuroprotective in vitro, but does not affect survival in SOD1 (G93A) mice. Neuroscience 220:26-31. |
|
|
Strong MJ (2010). The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS). J. Neurol. Sci. 288(1-2):1-12. |
|
|
Sunyach C, Michaud M, Arnoux T, Bernard-marrisal N (2012). Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in na als mouse model. Neuropharmacology 62:2346-2353. |
|
|
Tanaka K, Kanno T, Yanagisawa Y, Yasutake K, Hadano S, Yoshii F, Ikeda JE (2011). Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 232(1):41-52. |
|
|
Tanaka K, Kanno T, Yanagisawa Y, Yasutake K, Inoue S, Hirayama N, Ikeda JE (2014). A novel acylaminoimidazole derivative, WN1316, alleviates disease progression via suppression of glial inflammation in ALS mouse model. PLoS ONE 9(1):e87728. |
|
|
The Amyotrophic Lateral Sclerosis Functional Rating Scale (1996). Assessment of activities of daily living in patients with amyotrophic lateral sclerosis The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurol. 53:141-147. |
|
|
Tovar-y-Romo LB, Tapia R (2012). Delayed administration of VEGF rescues spinal motor neurons from death with a short effective time frame in excitotoxic experimental models in vivo. ASN NEURO. 4(2):e00081. |
|
|
Towne C, Setola V, Schneider BL, Aebischer P (2011). Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice. Mol. Ther. 19(2):274-283. |
|
|
Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, Cudkowicz ME (2006). Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 67(1):20-27. |
|
|
UKMND-LiCALS Study Group (2013). Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol.12(4):339-345. |
|
|
Verstraete E, Veldink JH, Huisman MH, Draak T, Uijtendaal EV, van der Kooi AJ, Schelhaas HJ, de Visser M, van der Tweel I, van den Berg LH (2012). Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. J. Neurol. Neurosurg. Psychiatry 83(5):557-564. |
|
|
Wang L, Popko B, Tixier E, Roos RP (2014). Guanabenz, which enhances the unfolded protein response, ameliorates mutant SOD1-induced amyotrophic lateral sclerosis. Neurobiol. Dis. 71: 317-324. |
|
|
Yazhou L, Srinivaslu H, Mohamed W (2012). Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis. PLoS ONE 7(2):E 32008. |
|
|
Yoo YE, Ko CP (2011). Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis. Exp Neurol. 231(1):147-159. |
|
|
Yoo YE, Ko CP (2012). Dihydrotestosterone ameliorates degeneration in muscle, axons and motoneurons and improves motor function in amyotrophic lateral sclerosis model mice. PLoS ONE 7(5):e37258. |
|
|
Zhao W, Varghese M, Vempati P, Dzhun A, Cheng A, Wang J, Lange D, Bilski A, Faravelli I, Pasinetti GM (2012). Caprylic Triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS disease. PloS ONE 7(11):e49191. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
